IBRX vs PAYC · rev $113.3M vs P/E 33, rev $1.88B
Immunitybio Inc (IBRX) versus Paycom Soft (PAYC) — a side-by-side from cached financials, not a winner call.
Immunitybio Inc (IBRX) is a biotechnology company listed on US.
Paycom Soft (PAYC) is a software - application company listed on US.
Latest reported IBRX revenue for 2025-12-31 was $113.3M. Net income was -$351.4M. Revenue was up 668.3% from 2024-12-31 to 2025-12-31. IBRX currently screens at market cap $7.88B.
Latest reported PAYC revenue for 2024-12-31 was $1.88B. Net income was $502.0M. Revenue was up 11.2% from 2023-12-31 to 2024-12-31. PAYC currently screens at market cap $13.06B and trailing P/E 33.1.
IBRX currently screens at market cap $7.88B. PAYC currently screens at market cap $13.06B and trailing P/E 33.1.
Not investment advice. Open the IBRX and PAYC stock pages for the full models.
Not investment advice.